Opportunity ID: 307791

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-HL-18-033
Funding Opportunity Title: Regenerative Medicine Innovation Projects (RMIP) (UT2 – Clinical Trial Not Allowed)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Food and Nutrition
Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.121 — Oral Diseases and Disorders Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Aug 01, 2018
Last Updated Date:
Original Closing Date for Applications: Oct 19, 2018
Current Closing Date for Applications: Oct 19, 2018
Archive Date: Nov 24, 2018
Estimated Total Program Funding:
Award Ceiling: $225,000
Award Floor:

Eligibility

Eligible Applicants: Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Additional Information

Agency Name: National Institutes of Health
Description: The National Institutes of Health (NIH), participating NIH Institutes and Centers, in coordination with the U.S. Food and Drug Administration, invite cooperative agreement (UT2) applications to support small business research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. These applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective RM therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of in-depth product characterization, manufacturing, potency, identity, quality, safety, in vivo function and integration, or effectiveness. Toward these ends, the NIH will consider applications for late stage preclinical research studies involving adult stem cells in the context of generating or supplementing the necessary evidence for clinical development, including, but not limited to, the submission of an Investigational New Drug (IND) or Investigational New Device Exemption (IDE) package; or to support such research conducted under an authorized IND or IDE.
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-18-033.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email:FBOWebmaster@OD.NIH.GOV

Version History

Version Modification Description Updated Date

Related Documents

Packages

Agency Contact Information: NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email: FBOWebmaster@OD.NIH.GOV

Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
FORMS-E FORMS-E PKG00244203 Sep 19, 2018 Oct 19, 2018 View

Package 1

Mandatory forms

307791 RR_SF424_2_0-2.0.pdf

307791 PHS398_CoverPageSupplement_4_0-4.0.pdf

307791 RR_OtherProjectInfo_1_4-1.4.pdf

307791 PerformanceSite_2_0-2.0.pdf

307791 RR_KeyPersonExpanded_2_0-2.0.pdf

307791 RR_Budget_1_4-1.4.pdf

307791 RR_SubawardBudget30_1_4-1.4.pdf

307791 PHS398_ResearchPlan_4_0-4.0.pdf

307791 SBIR_STTR_Information_1_2-1.2.pdf

Optional forms

307791 PHS_AssignmentRequestForm_2_0-2.0.pdf

2025-07-09T19:14:20-05:00

Share This Post, Choose Your Platform!

About the Author: